NEW YORK, Jan. 18, 2018 /PRNewswire/ --WallStEquities.com strives to bring the best free research to the investment community.Today we are offering reports on ARAY, KTWO, NUVA, and NVCR which can be accessed for free by signing up to www.wallstequities.com/registration. For today, WallStEquities.com shifts focus on Accuray Inc. (NASDAQ: ARAY), K2M Group Holdings Inc. (NASDAQ:
On Wednesday, shares in Sunnyvale, California headquartered Accuray Inc. recorded a trading volume of 1.56 million shares, which was above their three months average volume of 1.08 million shares. The stock ended at $5.20, jumping 4.00% from the last trading session. The Company's shares have gained 16.85% in the last month and 23.81% over the previous three months. The stock is trading above its 50-day and 200-day moving averages by 9.81% and 17.07%, respectively. Furthermore, shares of Accuray, which designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body, have a Relative Strength Index (RSI) of 65.12.
On January 11th, 2018, Accuray announced the appointment of Beverly A. Huss to its Board of Directors, effective January 07th, 2018. Ms. Huss also currently serves on the boards of Qool Therapeutics, Inc., Surefire Medical, Inc., and Madorra. Get the full research report on ARAY for free by clicking below at:
K2M Group Holdings
Leesburg, Virginia headquartered K2M Group Holdings Inc.'s stock finished yesterday's session 1.62% higher at $20.69. A total volume of 352,990 shares was traded, which was above their three months average volume of 345,340 shares. The Company's shares have gained 19.04% in the last month and 6.54% over the previous three months. The stock is trading above its 50-day moving average by 10.87%. Furthermore, shares of K2M Group, which focuses on designing, developing, and commercializing spine and minimally invasive solutions in the US and internationally, have an RSI of 69.63.
On December 20th, 2017, K2M Group announced that it received a CE Mark for its CAPRI® Cervical 3D Expandable Corpectomy Cage System featuring Lamellar 3D Titanium Technology™, and the successful completion of its first surgical case. CAPRI Cervical 3D Expandable is the world's first and only 3D-printed expandable device on the market to facilitate continuous in-situ height expansion and endplate angulation in the cervical spine.
On January 09th, 2018, research firm Needham reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $20 a share to $23 a share. The free technical report on KTWO can be accessed at:
On Wednesday, shares in San Diego, California headquartered NuVasive Inc. dropped 3.27%, ending the day at $50.29. The stock recorded a trading volume of 2.11 million shares, which was above its three months average volume of 869,000 shares. The Company's shares are trading 12.46% below their 50-day moving average. Moreover, shares of NuVasive have an RSI of 27.71.
On January 04th, 2018, NuVasive announced the launch of the Company's COALESCETM Thoracolumbar Interbody Fusion Device, as well as FDA 510(k) clearance for expanded indications of its COHERE® Cervical Interbody Fusion Device. The launch and updated claims follow the Company's September 2017 acquisition of Vertera Spine, developers of highly innovative interbody implants for spinal fusion using patented porous polyetheretherketone (PEEK) technology. COALESCE and COHERE provide a unique, three-dimensional Porous PEEK™ architecture to help elicit and encourage bone ingrowth.
On January 17th, 2018, research firm Wells Fargo downgraded the Company's stock rating from 'Outperform' to 'Market Perform'. Sign up for free on Wall St. Equities and claim the latest report on NUVA at:
Saint Helier, the Channel Islands-based NovoCure Ltd's shares ended the day 2.12% lower at $20.75. A total volume of 1.08 million shares was traded, which was above their three months average volume of 913,050 shares. The stock has gained 4.01% in the last month, 17.56% over the previous three months, and 214.39% over the past year. The Company's shares are trading 4.49% above their 50-day moving average and 19.14% above their 200-day moving average. Additionally, shares of NovoCure have an RSI of 52.95.
On January 09th, 2018, NovoCure announced that it will report its financial results for Q4 and full year 2017 on February 22nd, 2018, before the US financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET that same day to provide a Company update and discuss its financial results. The webcast can be accessed live under the Investor Relations page of the Company's website. See the free research coverage on NVCR at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email: email@example.com Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/quotidian-technical-highlights-on-selected-medical-equipment-stocks----accuray-k2m-group-nuvasive-and-novocure-300584501.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
DOOR syndrome is a rare genetic disorder marked by deafness, short or absent fingernails, abnormal ...
Are you gluten intolerant? Stay away from gluten allergy and celiac disease by shifting to ...
Moxetumomab pasudotox-tdfk is used to treat hairy cell leukemia (a form of chronic lymphocytic ...View All